Lexeo Therapeutics Income Statement (2022-2023) | LXEO

Income Statement Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023
Revenue & cost
Revenue 0.53M-0.05M-0.05M-0.05M-0.05M-0.05M
Operating items
Research & Development 15.36M11.39M16.44M11.24M17.25M8.21M
Selling, General & Administrative 2.65M3.81M2.85M2.74M3.03M6.76M
Operating Expenses 18.01M15.20M19.29M13.97M20.27M14.97M
Operating Income -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M
EBIT -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M
Non-operating items
Interest & Investment Income 0.46M0.68M0.69M0.59M0.49M1.10M
Other Non Operating Income -0.00M-0.00M0.00M-0.01M
Non Operating Income 0.43M0.62M0.63M0.53M0.17M0.79M
Net income details
EBT -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M
Profit After Tax -17.05M-14.60M-18.66M-13.44M-20.11M-14.19M
Income from Continuing Operations -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M
Consolidated Net Income -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M
Income towards Parent Company -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M
Net Income towards Common Stockholders -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M
Additional items
EPS (Basic) -10.38-8.86-11.58-8.30-12.3619.84
EPS (Weighted Average and Diluted) -10.38-8.86-11.58-8.30-12.3619.84
Shares Outstanding (Weighted Average) 15.67M15.67M15.67M15.67M26.65M
Shares Outstanding (Diluted Average) 1.64M1.63M1.61M1.62M1.63M
EBITDA -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M
Interest Expenses 0.03M0.05M0.05M0.05M0.05M0.05M